Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme)

Business Data, Corporate Office and Headquarter Address

About

Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) is Buildings and Property in United States that focus on inhibitor program business. They cover business area such as Boxford, Massachusetts, an exemplary target, human genetic, variant, cholesterol.

Business Type

Buildings and Property

Country

United States

Founded

-

Company Focus

Inhibitor Program

Website

-

Corporate Office and Headquarter Office address:

4 Dana Road
Boxford, MA 01921
United States

Phone number:

Private

Office Opening Hours*:

Monday 9.30 - 17.00
Tuesday 9.30 - 17.00
Wednesday 9.30 - 17.00
Thursday 9.30 - 17.00
Friday 9.30 - 17.00
Saturday Closed
Sunday Closed

Business Coverage

BoxfordMassachusettsan exemplary targethuman geneticvariantcholesterol

* We use standard office opening hours in near Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.

Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) Frequently Asked Questions

What or who is Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme)?

Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) is Buildings and Property business from United States that founded in - ( years old in ), Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) business is focusing on Inhibitor Program.

Where is Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) headquarter and corporate office address?

Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) headquarter office and corporate office address is located in 4 Dana Road Boxford, MA 01921 United States.

Where is Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) country origins?

Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) was founded in United States.

What is Inhibitor Program business focus on?

In , Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) is currently focus on inhibitor program sector.

Inhibitor Program Business Interest from Google Trend

Above is snippet of Google Trends for "inhibitor program" term, if you have problem loading the snippet, please visit here: Google Trend.

Disclaimer: This website is not affiliated with Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.